Jeremy P. Springhorn, Chief Business Officer at Syros Pharmaceuticals, Inc. (SYRS), bought 15,000 shares at $9.08 ($136K) on 2017-12-15, disclosed to the SEC on 2017-12-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| QURE | SELL | 2024-06-17 | $11K | — | Filing → |
| QURE | SELL | 2023-06-20 | $43K | — | Filing → |
| QURE | SELL | 2023-03-01 | $8K | — | Filing → |